Centrosomal Protein 70 Is a Mediator of Paclitaxel Sensitivity
AbstractCentrosome aberrations have been implicated in the development and progression of breast cancer. Our previous worked show that centrosomal protein 70 (Cep70) regulates breast cancer growth and metastasis. However, it remains elusive whether Cep70 is implicated in the sensitivity of the anti-microtubule drug paclitaxel in breast cancer. Here we provide evidence that Cep70 is a mediator of paclitaxel sensitivity in breast cancer. Cell proliferation assays show that Cep70 expression correlates with paclitaxel sensitivity in breast cancer cell lines. In addition, paclitaxel sensitivity varies when altering Cep70 expression level. Mechanistic studies reveal that Cep70 interacts with tubulin, and promotes the ability of paclitaxel to stimulate microtubule assembly. These data demonstrate that Cep70 mediates paclitaxel sensitivity in breast cancer. View Full-Text
Share & Cite This Article
Shi, X.; Wang, Y.; Sun, X.; Wang, C.; Jiang, P.; Zhang, Y.; Huang, Q.; Liu, X.; Li, D.; Zhou, J.; Liu, M. Centrosomal Protein 70 Is a Mediator of Paclitaxel Sensitivity. Int. J. Mol. Sci. 2017, 18, 1267.
Shi X, Wang Y, Sun X, Wang C, Jiang P, Zhang Y, Huang Q, Liu X, Li D, Zhou J, Liu M. Centrosomal Protein 70 Is a Mediator of Paclitaxel Sensitivity. International Journal of Molecular Sciences. 2017; 18(6):1267.Chicago/Turabian Style
Shi, Xingjuan; Wang, Yujue; Sun, Xiaoou; Wang, Chan; Jiang, Peng; Zhang, Yu; Huang, Qinghai; Liu, Xiangdong; Li, Dengwen; Zhou, Jun; Liu, Min. 2017. "Centrosomal Protein 70 Is a Mediator of Paclitaxel Sensitivity." Int. J. Mol. Sci. 18, no. 6: 1267.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.